Researchers at the University of Minnesota have developed novel anti-cancer drugs to treat solid tumors. These "small molecules" belong to a class of pharmaceutical agents called anti-angiogenics. The new compounds are a refined form of drugs that effectively reduce blood flow to the tumor, thereby inhibiting tumor growth. The results of the study appear in the July 5 issue of the Journal of the National Cancer Institute.